Xiulei Zhang1, Jia Yin2, Haitao Li1, Shuguang Li1, John Walley3, Guanyang Zou3, Zhitong Zhang3, Xiaolin Wei2. 1. Center for TB Control, Shandong Provincial Chest Hospital, Shandong, China. 2. School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong, China. 3. Nuffield Centre for International Health and Development, University of Leeds, Leeds, UK.
Abstract
OBJECTIVE: Shandong Province has implemented the standardised treatment of multidrug-resistant tuberculosis (MDR-TB) supported by the Global Fund. The study aimed to understand the managements and delays of patients with MDR-TB before initiating their treatments. METHODS: All patients with MDR-TB who had completed intensive phase treatment from January 2010 to May 2012 were interviewed using a structured questionnaire. Delays and treatments were analysed. Diagnosis delay is defined as the period between having sputum smear results and drug susceptibility test (DST) results. Treatment delay was defined as starting MDR-TB treatment more than 2 days after receiving the diagnosis of MDR-TB. Total delay is the sum of diagnosis delay and treatment delay. RESULTS: In total, 110 patients with MDR-TB participated in the study. Median delay for diagnosis was 102 days. Over 80% of patients had a diagnosis delay longer than 90 days. MDR-TB treatments commenced after a median of 9 days after DST results, and over 37% of the patients with MDR-TB experienced treatment delays. Chronic cases or patients with indifferent attitude had significantly longer treatment delay than other groups (P = 0.03 and 0.03, respectively). During their delays, of 44 patients with retreatment failures, 12 (27.3%) were treated through adding single second line drugs (SLDs) to first-line regimens, and 25 (56.8%) were treated with first-line drugs. A high proportion of initial treatment failure/relapsed/returned cases (37%) and new cases (43%) were administered with SLDs. CONCLUSIONS: Most of the patients with MDR-TB experienced prolonged diagnosis delay, which was the most important factor contributing to the total delay. Misuse of SLDs during the days was common, so necessary training should be given to prevent irrational prescription of medications.
OBJECTIVE: Shandong Province has implemented the standardised treatment of multidrug-resistant tuberculosis (MDR-TB) supported by the Global Fund. The study aimed to understand the managements and delays of patients with MDR-TB before initiating their treatments. METHODS: All patients with MDR-TB who had completed intensive phase treatment from January 2010 to May 2012 were interviewed using a structured questionnaire. Delays and treatments were analysed. Diagnosis delay is defined as the period between having sputum smear results and drug susceptibility test (DST) results. Treatment delay was defined as starting MDR-TB treatment more than 2 days after receiving the diagnosis of MDR-TB. Total delay is the sum of diagnosis delay and treatment delay. RESULTS: In total, 110 patients with MDR-TB participated in the study. Median delay for diagnosis was 102 days. Over 80% of patients had a diagnosis delay longer than 90 days. MDR-TB treatments commenced after a median of 9 days after DST results, and over 37% of the patients with MDR-TB experienced treatment delays. Chronic cases or patients with indifferent attitude had significantly longer treatment delay than other groups (P = 0.03 and 0.03, respectively). During their delays, of 44 patients with retreatment failures, 12 (27.3%) were treated through adding single second line drugs (SLDs) to first-line regimens, and 25 (56.8%) were treated with first-line drugs. A high proportion of initial treatment failure/relapsed/returned cases (37%) and new cases (43%) were administered with SLDs. CONCLUSIONS: Most of the patients with MDR-TB experienced prolonged diagnosis delay, which was the most important factor contributing to the total delay. Misuse of SLDs during the days was common, so necessary training should be given to prevent irrational prescription of medications.
Keywords:
China; diagnosis delay; medicamentos de segunda línea; multidrug-resistant tuberculosis; médicaments de seconde ligne; retard de diagnostic; retard de traitement; retraso en el diagnóstico; retraso en el tratamiento; second-line drugs; treatment delay; tuberculose multirésistante; tuberculosis multirresistente
Authors: Palwasha Y Khan; Tom A Yates; Muhammad Osman; Robin M Warren; Yuri van der Heijden; Nesri Padayatchi; Edward A Nardell; David Moore; Barun Mathema; Neel Gandhi; Vegard Eldholm; Keertan Dheda; Anneke C Hesseling; Valerie Mizrahi; Roxana Rustomjee; Alexander Pym Journal: Lancet Infect Dis Date: 2018-12-13 Impact factor: 25.071
Authors: Alphonce A Liyoyo; Scott K Heysell; Riziki M Kisonga; Johnson J Lyimo; Liberate J Mleoh; Beatrice K Mutayoba; Isaack A Lekule; Blandina T Mmbaga; Gibson S Kibiki; Stellah G Mpagama Journal: East Afr Health Res J Date: 2017-03-01
Authors: Stellah G Mpagama; Mangi J Ezekiel; Peter M Mbelele; Anna M Chongolo; Gibson S Kibiki; Kristen Petros de Guex; Scott K Heysell Journal: BMC Public Health Date: 2020-11-07 Impact factor: 3.295
Authors: Rebecca C Harris; Louis Grandjean; Laura J Martin; Alexander J P Miller; Joseph-Egre N Nkang; Victoria Allen; Mishal S Khan; Katherine Fielding; David A J Moore Journal: BMC Infect Dis Date: 2016-05-04 Impact factor: 3.090
Authors: Ye Minn Htun; Tin Mi Mi Khaing; Yin Yin; Zaw Myint; Si Thu Aung; Tin Maung Hlaing; Ngamphol Soonthornworasiri; Udomsak Silachamroon; Yuthichai Kasetjaroen; Jaranit Kaewkungwal Journal: BMC Health Serv Res Date: 2018-11-20 Impact factor: 2.655
Authors: Ye Minn Htun; Tin Mi Mi Khaing; Nay Myo Aung; Yin Yin; Zaw Myint; Si Thu Aung; Ngamphol Soonthornworasiri; Udomsak Silachamroon; Yuthichai Kasetjaroen; Jaranit Kaewkungwal Journal: PLoS One Date: 2018-12-31 Impact factor: 3.240